einstein (São Paulo). 25/Feb/2019;17(2):eGS4414.

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Pedro Nazareth Aguiar Jr. ORCID logo , Pui San Tan ORCID logo , Sarah Simko ORCID logo , Carmelia Maria Noia Barreto ORCID logo , Bárbara de Souza Gutierres ORCID logo , Auro del Giglio ORCID logo , Gilberto de Lima Lopes Jr ORCID logo

DOI: 10.31744/einstein_journal/2019GS4414

ABSTRACT

Objective

To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation.

Methods

We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects.

Results

Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted Life Years. Abiraterone led to a Quality-Adjusted Life Years gain of 0.506 compared to docetaxel. The incremental costs per Quality-Adjusted Life Years were R$ 133.649,22 for docetaxel, R$ 330.828,70 for abiraterone and R$ 571.379,42 for abiraterone compared to docetaxel, respectively.

Conclusion

The addition of chemotherapy to androgen deprivation therapy is more cost-effective than the addition of abiraterone to androgen deprivation therapy. However, discounts on abiraterone cost might improve cost-effectiveness.

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Comments